Capital Research Global Investors grew its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 29.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,304,897 shares of the medical research company’s stock after buying an additional 3,973,136 shares during the quarter. Thermo Fisher Scientific makes up 0.9% of Capital Research Global Investors’ portfolio, making the stock its 27th largest position. Capital Research Global Investors owned 4.44% of Thermo Fisher Scientific worth $3,019,185,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in TMO. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 6.1% during the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after purchasing an additional 671,637 shares during the period. AHL Partners LLP raised its position in shares of Thermo Fisher Scientific by 242.1% during the second quarter. AHL Partners LLP now owns 24,130 shares of the medical research company’s stock worth $4,210,000 after purchasing an additional 17,076 shares during the period. Boston Common Asset Management LLC raised its position in Thermo Fisher Scientific by 13.1% in the 2nd quarter. Boston Common Asset Management LLC now owns 6,639 shares of the medical research company’s stock valued at $1,158,000 after buying an additional 770 shares during the last quarter. L & S Advisors Inc raised its position in Thermo Fisher Scientific by 23.0% in the 2nd quarter. L & S Advisors Inc now owns 4,515 shares of the medical research company’s stock valued at $788,000 after buying an additional 845 shares during the last quarter. Finally, Sun Life Financial INC raised its position in Thermo Fisher Scientific by 36,148.5% in the 2nd quarter. Sun Life Financial INC now owns 11,962 shares of the medical research company’s stock valued at $2,092,000 after buying an additional 11,929 shares during the last quarter. Institutional investors own 83.78% of the company’s stock.
In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares in the company, valued at approximately $6,702,635.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jim P. Manzi sold 1,000 shares of the stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. Insiders sold a total of 22,738 shares of company stock valued at $4,021,512 over the last 90 days. 0.49% of the stock is currently owned by company insiders.
Several research analysts have weighed in on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research report on Tuesday, October 31st. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. Deutsche Bank AG set a $226.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Jefferies Group LLC reissued a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $205.71.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at $186.18 on Monday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20. The firm has a market capitalization of $74,150.00, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.71 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 EPS. equities research analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.